Interviews with Key Healthcare Opinion Leaders - Episode #103

Dr. Andrew Hertler, Senior Advisor / Chief Medical Officer – emeritus for Evolent, explains ODAC’s September 2024 vote to support the FDA’s decision to restrict the use of PD-1 inhibitor drugs such as Opdivo, Keytruda, and Tevimbra for PD-L1-negative stomach cancer and esophageal cancer, and his support of using biomarkers to predict outcomes.